167 related articles for article (PubMed ID: 22371894)
1. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M; Fayet-Mello A; Lubomirov R; Neely M; di Iulio J; Owen A; Boffito M; Cavassini M; Günthard HF; Rentsch K; Buclin T; Aouri M; Telenti A; Decosterd LA; Rotger M; Csajka C;
Antimicrob Agents Chemother; 2012 Jun; 56(6):2959-66. PubMed ID: 22371894
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
3. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D;
PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
Dickinson L; Boffito M; Back D; Waters L; Else L; Davies G; Khoo S; Pozniak A; Aarons L
J Antimicrob Chemother; 2009 Jun; 63(6):1233-43. PubMed ID: 19329800
[TBL] [Abstract][Full Text] [Related]
5. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
6. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Savic RM; Barrail-Tran A; Duval X; Nembot G; Panhard X; Descamps D; Verstuyft C; Vrijens B; Taburet AM; Goujard C; Mentré F;
Clin Pharmacol Ther; 2012 Nov; 92(5):575-83. PubMed ID: 23033116
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C; Gaspar F; Aouri M; Panchaud A; Rotger M; Guidi M; Cavassini M; Buclin T; Decosterd LA; Csajka C;
J Antimicrob Chemother; 2016 Jul; 71(7):1933-42. PubMed ID: 27029846
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M; Barcelo C; Guidi M; Rotger M; Cavassini M; Hizrel C; Buclin T; Decosterd LA; Csajka C;
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799217
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R; Arab-Alameddine M; Rotger M; Fayet-Mello A; Martinez R; Guidi M; di Iulio J; Cavassini M; Günthard HF; Furrer H; Marzolini C; Bernasconi E; Calmy A; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2013 Jan; 23(1):9-18. PubMed ID: 23111422
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Dickinson L; Gurjar R; Stöhr W; Bonora S; Owen A; D'Avolio A; Cursley A; Molina JM; Fäetkenheuer G; Vandekerckhove L; Di Perri G; Pozniak A; Richert L; Raffi F; Boffito M;
J Antimicrob Chemother; 2020 Mar; 75(3):628-639. PubMed ID: 31754703
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):143-9. PubMed ID: 22421745
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Sukasem C; Punyawudho B
Pharmacogenomics; 2017 Nov; 18(16):1481-1490. PubMed ID: 29061086
[TBL] [Abstract][Full Text] [Related]
17. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Siccardi M; DʼAvolio A; Rodriguez-Novoa S; Cuenca L; Simiele M; Baietto L; Calcagno A; Moss D; Bonora S; Soriano V; Back DJ; Owen A; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):232-5. PubMed ID: 22406652
[TBL] [Abstract][Full Text] [Related]
18. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
[TBL] [Abstract][Full Text] [Related]
20. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
